Zimmer BioTech is a drug-development spin-off from Zimmer MedizinSysteme GmbH based in Neu-Ulm, Germany. It is advancing Alevin deep, a drug based on 5‑Aminolevulinic acid (ALA) intended for use in treating actinic keratoses and as a therapy to combat skin cancer. The company has implemented a pharmaceutical-focused quality management system to meet legal requirements for drug development. Management plans to begin human clinical testing of Alevin deep in the near future, with regulatory approval anticipated in 2020. Financially, Zimmer BioTech raised funding to support continued development of the therapy. The spin-off structure and backing from its parent device producer inform its strategic and operational setup.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2017